Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-blind, Randomized Phase II Clinical Trial of Sulindac for Reducing Breast Density in Postmenopausal Women at Risk of Developing Breast Cancer

NCT04542135 is registered in ClinicalTrials.gov with Alison Stopeck as lead sponsor.

NCT NCT04542135
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04542135 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-blind, Randomized Phase II Clinical Trial of Sulindac for Reducing Breast Density in Postmenopausal Women at Risk of Developing Breast Cancer
Lead sponsor
Alison Stopeck
Phase
Phase 2
Overall status
Completed
Start date
November 20, 2020
Completion date
May 19, 2025
Enrollment
61 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer